H. Strongman

First name
H.
Last name
Strongman
Davidson, J. A., Banerjee, A., Strongman, H., Herrett, E., Smeeth, L., Breuer, J., & Warren-Gash, C. (2023). Acute Cardiovascular Events After COVID-19 in England in 2020: A Self-Controlled Case Series Study. Clin Epidemiol, 15, 911-921. http://doi.org/10.2147/clep.s421062
View
Andresen, K., Carreira, H., Strongman, H., McDonald, H. I., Benitez-Majano, S., Mansfield, K. E., et al. (2023). The risk of acute kidney injury in colorectal cancer survivors: an english population-based matched cohort study. Bmc Cancer, 23, 839. http://doi.org/10.1186/s12885-023-11329-9
View
Warren-Gash, C., Davidson, J. A., Strongman, H., Herrett, E., Smeeth, L., Breuer, J., & Banerjee, A. (2023). Severe COVID-19 outcomes by cardiovascular risk profile in England in 2020: a population-based cohort study. Lancet Reg Health Eur, 27, 100604. http://doi.org/10.1016/j.lanepe.2023.100604
View
Strongman, H., Gadd, S., Matthews, A. A., Mansfield, K. E., Stanway, S., Lyon, A. R., et al. (2022). Does Cardiovascular Mortality Overtake Cancer Mortality During Cancer Survivorship?: An English Retrospective Cohort Study. Jacc Cardiooncol, 4, 113-123. http://doi.org/10.1016/j.jaccao.2022.01.102
View
Strongman, H., Carreira, H., De Stavola, B. L., Bhaskaran, K., & Leon, D. A. (2022). Factors associated with excess all-cause mortality in the first wave of the COVID-19 pandemic in the UK: A time series analysis using the Clinical Practice Research Datalink. Plos Med, 19, e1003870. http://doi.org/10.1371/journal.pmed.1003870
View
Herrett, E., Strongman, H., Gadd, S., Tomlinson, L., Nitsch, D., Bhaskaran, K., et al. (2022). The importance of blood pressure thresholds versus predicted cardiovascular risk on subsequent rates of cardiovascular disease: a cohort study in English primary care. Lancet Healthy Longev, 3, e22-e30. http://doi.org/10.1016/s2666-7568(21)00281-6
View
Das, R., Langerman, H., D'Oca, K., & Strongman, H. (2014). An Observational Cohort Study of Diabetes-Associated Secondary Health Care Utilisation in Patients With Type 2 Diabetes Prescribed Dual Combination Therapy With Oral Anti-Hyperglycaemic Agents in the UK. Value Health. http://doi.org/10.1016/j.jval.2014.08.782
View
Strongman, H., D'Oca, K., Langerman, H., & Das, R. (2015). Comparison of diabetes-associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.12458
View
Korhonen, P., Heintjes, E. M., Williams, R., Hoti, F., Christopher, S., Majak, M., et al. (2016). Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. Bmj. http://doi.org/10.1136/bmj.i3903
View
Strongman, H., Korhonen, P., Williams, R., Bahmanyar, S., Hoti, F., Christopher, S., et al. (2017). Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2016-000364
View